Keyphrases
Immunohistochemistry
100%
Fluorescence in Situ Hybridization
100%
Cyclin D1 (CCND1)
100%
Plasma Cell Myeloma
100%
Fusion Status
36%
Negative Predictive Value
18%
Validation Cohort
9%
Standard of Care
9%
Positive Predictive Value
9%
Classification System
9%
Core Needle Biopsy
9%
Novel Therapies
9%
Myeloma
9%
Immunohistochemical Staining
9%
Plasma Cells
9%
Fluorescence in Situ Hybridization Analysis
9%
Risk-benefit Ratio
9%
Immunohistochemical Expression
9%
Turnaround Time
9%
Bone Marrow Aspirate
9%
Bone Marrow Biopsy
9%
Favorable Risk
9%
Bcl-2 Inhibitor
9%
H-score
9%
Multi-tiered
9%
Venetoclax
9%
Cell Purification
9%
Sample Cell
9%
Medicine and Dentistry
Fluorescence in Situ Hybridization
100%
Immunohistochemistry
100%
Multiple Myeloma
100%
Cyclin D1
57%
Health Care Cost
14%
Risk-Benefit Ratio
14%
Myeloma
14%
Biopsy Technique
14%
Copurification
14%
Bone Marrow Biopsy
14%
Venetoclax
14%
Immunoglobulin Producing Cell
14%
Oral
14%
Neuroscience
Immunohistochemistry
100%
In Situ Hybridization
100%
Immunoglobulin Producing Cell
100%
Cyclin D1
57%
Staining Technique
14%
Biochemistry, Genetics and Molecular Biology
Fluorescence in Situ Hybridization
100%
Immunoglobulin Producing Cell
100%
Cyclin D1
57%
Copurification
14%
Turnaround Time
14%